| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 02/20/2001 | CA2119651C Immunoassay for identifying alcoholics and monitoring alcohol consumption |
| 02/20/2001 | CA2084386C Hiv antigen |
| 02/20/2001 | CA2033730C Heparin-binding growth factor |
| 02/20/2001 | CA1341185C Intercellular adhesion molecules and their binding ligands |
| 02/20/2001 | CA1341182C Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
| 02/20/2001 | CA1341181C Vaccines based on membrane bound proteins and process for making them |
| 02/15/2001 | WO2001011533A1 Method of recording gene analysis data |
| 02/15/2001 | WO2001011369A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 02/15/2001 | WO2001011366A1 Antigenic components of selected indicator fungi and their use in methods and test kits |
| 02/15/2001 | WO2001011351A1 Method for detecting single nucleotide polymorphism (snp) and point mutation in gene, detection apparatus and detection chip |
| 02/15/2001 | WO2001011341A2 A system for cell-based screening |
| 02/15/2001 | WO2001011340A1 Optical system analysis of cells |
| 02/15/2001 | WO2001011336A1 Direct aspiration-reaction and injection device and methods of use |
| 02/15/2001 | WO2001011335A2 Antiviral compounds that inhibit viral replication |
| 02/15/2001 | WO2001011333A2 Apparatus for real-time measurement of cellular response |
| 02/15/2001 | WO2001011089A1 Novel method for screening compound for preventing or treating liver cell injury caused by hepatitis c virus and compound obtained by this method |
| 02/15/2001 | WO2001011088A2 Methods to identify evolutionarily significant changes in polynucleotide and polypeptide sequences in domesticated plants and animals |
| 02/15/2001 | WO2001011087A2 Method of evaluating a gene transfer vector and gene transfer vector product interactions |
| 02/15/2001 | WO2001011086A2 Methods of screening for angiogenesis modulators |
| 02/15/2001 | WO2001011083A2 Methods for detecting mutations using primer extension |
| 02/15/2001 | WO2001011082A2 Methods of gene expression monitoring |
| 02/15/2001 | WO2001011081A2 Microbial polynucleotides expressed during infection of a host |
| 02/15/2001 | WO2001011078A1 Amplification method for detection of target nucleic acids involving fluorescence energy transfer |
| 02/15/2001 | WO2001011075A2 Pcr-based detection and quantification of tapesia yallundae and tapesia acuformis |
| 02/15/2001 | WO2001011071A2 Bioproduction of para-hydroxycinnamic acid |
| 02/15/2001 | WO2001011069A1 Freeze/thawed lipid complexes and their preparation |
| 02/15/2001 | WO2001011068A2 Cationic lipid compounds and use thereof for transferring negatively charged substances of therapeutic interest |
| 02/15/2001 | WO2001011067A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 02/15/2001 | WO2001011066A1 Non-human adenoviral vector for gene transfer, its use and the production thereof |
| 02/15/2001 | WO2001011065A2 Hepatitis a virus clones adapted for growth in agmk cells |
| 02/15/2001 | WO2001011064A2 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy |
| 02/15/2001 | WO2001011063A2 Gene transfer combination vectors, method for the production and utilization thereof |
| 02/15/2001 | WO2001011062A2 Polyamine accumulation in plants |
| 02/15/2001 | WO2001011061A2 Regulation of embryonic transcription in plants |
| 02/15/2001 | WO2001011060A2 Method of isolating secretion signals in lactic acid bacteria and novel secretion signals isolated from lactococcus lactis |
| 02/15/2001 | WO2001011058A1 Novel cloning methods and vectors |
| 02/15/2001 | WO2001011057A1 Production of proteins |
| 02/15/2001 | WO2001011056A1 Production of proteins by autoproteolytic cleavage |
| 02/15/2001 | WO2001011055A1 Isoprenoid biosynthesis |
| 02/15/2001 | WO2001011054A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 02/15/2001 | WO2001011053A2 Soluble, active recombinant human mao-b |
| 02/15/2001 | WO2001011052A2 Monocellular or multicellular organisms for the production of riboflavin |
| 02/15/2001 | WO2001011051A2 Chimeric proteins |
| 02/15/2001 | WO2001011050A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
| 02/15/2001 | WO2001011049A2 Methods and compositions concerning canine interleukin 5 |
| 02/15/2001 | WO2001011048A2 Therapeutic polypeptides and methods for using same |
| 02/15/2001 | WO2001011047A2 Dna sequences isolated from human colonic epithelial cells |
| 02/15/2001 | WO2001011046A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | WO2001011045A1 A human lactoferrin produced by using an insect cell and method using the same |
| 02/15/2001 | WO2001011044A1 Tumor antigen |
| 02/15/2001 | WO2001011043A1 Single-chain polypeptides comprising troponin i n-terminal fragments and troponin c |
| 02/15/2001 | WO2001011042A1 Dapp1, a dual adaptor for phosphotyrosine and 3-phosphoinositides |
| 02/15/2001 | WO2001011041A1 MONOMERIC PROTEIN OF THE TGF-β FAMILY |
| 02/15/2001 | WO2001011040A1 Tumor-associated antigen (r11) |
| 02/15/2001 | WO2001011039A2 New sequence variants of the human 1-adrenoreceptor gene and use thereof |
| 02/15/2001 | WO2001011038A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 02/15/2001 | WO2001011037A1 Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| 02/15/2001 | WO2001011036A1 Method of enhancing plant resistance to pathogens |
| 02/15/2001 | WO2001011035A1 Monoclonal antibodies for human cytochrome p450 3a4 and human cytochrome p450 2c9 |
| 02/15/2001 | WO2001011034A2 Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| 02/15/2001 | WO2001011033A2 Identification of genes essential for the survival of haemophilus influenzae through genome scanning by transposition mutagenesis |
| 02/15/2001 | WO2001011030A2 Method and means for inducing cell-multiplication of non-active cells |
| 02/15/2001 | WO2001011029A1 Transgenic plants expressing photorhabdus toxin |
| 02/15/2001 | WO2001011028A1 Glucuronoxylomannan (gxm)-o-acetylhydrolase of cryptococcus neoformans and uses thereof |
| 02/15/2001 | WO2001011027A1 New protein |
| 02/15/2001 | WO2001011024A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 02/15/2001 | WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | WO2001011022A1 Mouse g-protein coupled receptor edg3 |
| 02/15/2001 | WO2001011020A1 Method of making plant artificial chromosomes |
| 02/15/2001 | WO2001011014A1 Process for producing copolymerized polyester |
| 02/15/2001 | WO2001011010A2 Drug target isogenes: polymorphisms in the immunoglobulin e receptor i alpha subunit gene |
| 02/15/2001 | WO2001011008A2 Process for obtaining and detecting gram-positive fluorescent bacteria |
| 02/15/2001 | WO2001010912A1 Multiple cytokine-antibody complexes |
| 02/15/2001 | WO2001010910A1 Diagnostic method using expression of mn/ca9 protein in ascus pap smears |
| 02/15/2001 | WO2001010909A1 Diagnostic method using expression of mn/ca9 protein in agus pap smears |
| 02/15/2001 | WO2001010908A1 Ntr3, a member of the tnf-receptor supergene family |
| 02/15/2001 | WO2001010907A2 Therapeutic polypeptides and methods for using same |
| 02/15/2001 | WO2001010905A1 Medicinal compositions for inhibiting abnormal proliferation of vascular smooth muscle cells |
| 02/15/2001 | WO2001010904A1 Map |
| 02/15/2001 | WO2001010903A2 Proteases and protease inhibitors |
| 02/15/2001 | WO2001010902A2 Nucleoc acids and secreted polypeptides encoded thereby |
| 02/15/2001 | WO2001010896A2 Factor x analog with an improved ability to be activated |
| 02/15/2001 | WO2001010893A2 Il-16 antagonists |
| 02/15/2001 | WO2001010892A2 Peptide antagonists of factor viia |
| 02/15/2001 | WO2001010888A1 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis |
| 02/15/2001 | WO2001010886A2 Automated protein purification in the multiwell format by vacuum filtration |
| 02/15/2001 | WO2001010884A1 Drug target isogenes: polymorphisms in the 5-hydroxytryptamine receptor 1a gene |
| 02/15/2001 | WO2001010554A2 Laboratory robot and method and reagent kit for isolating nucleic acids |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010220A2 Insect control system |
| 02/15/2001 | WO2001010204A1 Non-mammalian transgenic animal model for cellular proliferative diseases |
| 02/15/2001 | WO2001010203A2 Non-human transgenic animals for the study of neurodegenerative syndromes |
| 02/15/2001 | WO2001010199A1 A knockout mouse for the tumor suppressor gene anx7 |
| 02/15/2001 | WO2000078984A3 Enhanced floral sink strength and increased stability of seed set in plants |
| 02/15/2001 | WO2000071724A3 Novel compounds from moraxella catarrhalis |
| 02/15/2001 | WO2000071698A3 Mixture for neutralizing enzyme inhibitors |
| 02/15/2001 | WO2000070016A3 Genetically modified plants tolerant of stress conditions |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000069872A3 pH DEPENDENT ION EXCHANGE MATRIX AND METHOD OF USE IN THE ISOLATION OF NUCLEIC ACIDS |